|

Vebreltinib combined with Furmonertinib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Peking University Cancer Hospital & Institute1

Indications

  • Non-small Cell Lung Cancer (NSCLC)1
  • Lung Cancer1
  • Cancer1

Other1 trial

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.